Systemic therapy and novel agents for metastatic castration resistant prostate cancer

[1]  B. Esterni,et al.  Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Vessella,et al.  The Prostate 68 : 861 ^ 871 ( 2008 ) RAD 001 ( Everolimus ) InhibitsGrowthof Prostate Cancer in theBone andthe Inhibitory EffectsAre IncreasedbyCombinationWithDocetaxel andZoledronicAcid , 2008 .

[3]  J. Witjes,et al.  Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial , 2008 .

[4]  F. Saad,et al.  A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel , 2008 .

[5]  M. Cooney,et al.  Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial , 2008 .

[6]  H. Parnes,et al.  Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC) , 2008 .

[7]  G. Sonpavde,et al.  Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy , 2008 .

[8]  F. Saad,et al.  A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy , 2008 .

[9]  M. Gross,et al.  Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study , 2008 .

[10]  C. Logothetis,et al.  Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results , 2008 .

[11]  W. Rathmell,et al.  A phase II trial of lapatinib in hormone refractory prostate cancer , 2008 .

[12]  Zhengxin Wang,et al.  Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. , 2008, Cancer research.

[13]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[14]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Jonas,et al.  New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma , 2008, Journal of cellular and molecular medicine.

[16]  M. Gleave,et al.  A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer , 2008, Clinical Cancer Research.

[17]  E. Messing,et al.  Androgen deprivation therapy for prostate cancer , 2008, Expert opinion on pharmacotherapy.

[18]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Steinberg,et al.  A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[20]  G. Sonpavde,et al.  Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. , 2007, Clinical genitourinary cancer.

[21]  K. Pienta,et al.  In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. , 2007, Neoplasia.

[22]  D. Strumberg,et al.  A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV , 2007, British Journal of Cancer.

[23]  F. Saad,et al.  A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer , 2007, Cancer.

[24]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[25]  J. Pignon,et al.  Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. , 2007, The Lancet. Oncology.

[26]  V. Castronovo,et al.  A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.

[27]  M. Rubin,et al.  A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer , 2007, BJU international.

[28]  Elizabeth Garrett-Mayer,et al.  Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Gross,et al.  Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients , 2007, Cancer.

[30]  M. Gross,et al.  A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer , 2007, BMC cancer.

[31]  S. Larson,et al.  Phase I study of docetaxel and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC) , 2007 .

[32]  K. Pienta,et al.  Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC) , 2007 .

[33]  I. Tannock,et al.  A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) , 2007 .

[34]  A. Brú.  Re: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor: B. I. Rini, L. Fong, v. Weinberg, B. Kavanaugh and E. J. Small. J Urol 2006; 175: 2087-2091. , 2007, The Journal of urology.

[35]  E. Small,et al.  A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.

[36]  C. Redfern,et al.  Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Parker,et al.  Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Jimeno,et al.  Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists , 2006, Clinical Cancer Research.

[39]  R. Herbst,et al.  Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Small,et al.  Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. , 2006, The Journal of urology.

[42]  C. Tangen,et al.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.

[43]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[44]  C. Tangen,et al.  Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[47]  M. Gleave,et al.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. , 2005, Journal of the National Cancer Institute.

[48]  H. Scher,et al.  Second-line chemotherapy for prostate cancer: patient characteristics and survival. , 2005, Clinical prostate cancer.

[49]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Cedarbaum,et al.  Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors , 2005 .

[51]  David C. Smith,et al.  Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC) , 2005 .

[52]  M. Poupon,et al.  Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Gleave,et al.  A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer , 2005, Clinical Cancer Research.

[54]  L. Collette,et al.  Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.

[55]  I. Tannock,et al.  Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.

[56]  David C. Smith,et al.  Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  C. Ryan,et al.  Phase II study of transdermal estradiol in androgen‐independent prostate carcinoma , 2005, Cancer.

[58]  L. Seymour,et al.  Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Berlin,et al.  Thromboembolic events with estramustine phosphate‐based chemotherapy in patients with hormone‐refractory prostate carcinoma , 2004, Cancer.

[60]  E. White,et al.  Epothilone induced cytotoxicity is dependent on p53 status in prostate cells , 2004, The Prostate.

[61]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[62]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[63]  S. Dakhil,et al.  Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. , 2004, Clinical prostate cancer.

[64]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  S. Vallabhajosula,et al.  Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[67]  J. Doroshow,et al.  Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma , 2004, Cancer.

[68]  P. Ell,et al.  Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. , 2004, Urology.

[69]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  W. Oh,et al.  A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma , 2003, Cancer.

[71]  E. Small,et al.  Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Nelson,et al.  Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. , 2003, The Journal of urology.

[73]  S. Dakhil,et al.  Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. , 2002, The Journal of urology.

[74]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[75]  E. Small,et al.  Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. , 2002, The Journal of urology.

[76]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  M. Zahurak,et al.  Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma , 2002, Cancer.

[78]  V. Reuter,et al.  Cytotoxic Treatment of Aggressive Prostate Tumors with or without Neuroendocrine Elements , 2002, Acta oncologica.

[79]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[80]  T. Beer,et al.  Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  S. Dakhil,et al.  Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. , 2001, Seminars in oncology.

[82]  S. Steinberg,et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  E. Small,et al.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Terry L. Smith,et al.  Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial , 2001, The Lancet.

[85]  D. Lake,et al.  A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma , 2000, Cancer.

[86]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[87]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  L. Einhorn,et al.  Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Picus,et al.  Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. , 1999, Seminars in oncology.

[90]  M. Benson,et al.  Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. , 1999, Seminars in oncology.

[91]  P. Kantoff,et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  N. Dawson.  Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  R. Day,et al.  Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. , 1997, Urology.

[94]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[95]  L. Schwartz,et al.  Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  P. Schellhammer,et al.  Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. , 1997, The Journal of urology.

[97]  E. Small,et al.  Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. , 1997, The Journal of urology.

[98]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  F. Boccardo,et al.  Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. , 1995, Anticancer research.

[100]  E. Small,et al.  The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer , 1995, Cancer.

[101]  J. Fowler,et al.  Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. , 1995, The Journal of urology.

[102]  E. Crawford,et al.  Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  D. Trump,et al.  Importance of continued testicular suppression in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[105]  W. Whitmore,et al.  The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. , 1981, The Journal of urology.

[106]  W. Whitmore,et al.  A critical analysis of response criteria in patients with prostatic cancer treated with CIS‐diamminedichloride platinum II , 1979, Cancer.

[107]  L. Seymour,et al.  A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  Hideo Araki,et al.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.

[109]  M. Egorin,et al.  Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer , 2003 .

[110]  P. Kantoff,et al.  Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  G. Bubley,et al.  High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.